AI Engines For more Details: Perplexity Kagi Labs You
Anti-Estrogenic Effects: Epitiostanol has been studied for its ability to block the effects of estrogen in the body. It may act as a competitive inhibitor of estrogen receptors, potentially reducing the effects of estrogen on target tissues. This property could be beneficial in certain medical conditions where estrogenic activity needs to be suppressed, such as hormone-sensitive cancers like breast cancer.
Androgenic Effects: Like other DHT derivatives, epitiostanol has androgenic properties, meaning it can bind to and activate androgen receptors in the body. This may result in effects such as increased muscle mass, strength, and libido. These androgenic effects could be relevant in conditions where androgen replacement therapy is indicated, such as androgen deficiency syndromes.
Anabolic Effects: Epitiostanol has been investigated for its potential as an anabolic steroid, although its efficacy and safety profile in this regard are not well-established. Anabolic steroids are sometimes used illicitly by athletes and bodybuilders to enhance muscle growth and performance.
Side Effects and Risks: Like other androgenic compounds, epitiostanol may be associated with a range of side effects and risks, including but not limited to liver toxicity, cardiovascular effects (such as changes in cholesterol levels and increased risk of cardiovascular disease), and suppression of natural testosterone production. Additionally, epitiostanol may have masculinizing effects in women, including virilization (development of male secondary sexual characteristics).
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.6 | -1 |
| ADHD | 1.3 | 1.3 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1 | 0.7 | 0.43 |
| Allergies | 0.4 | 0.8 | -1 |
| Allergy to milk products | 0.3 | 0.7 | -1.33 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 1 | 2 | -1 |
| Ankylosing spondylitis | 1.4 | 0.3 | 3.67 |
| Anorexia Nervosa | 0.7 | 1.1 | -0.57 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 1.1 | 1.1 | 0 |
| Atherosclerosis | 0.3 | 1.2 | -3 |
| Atrial fibrillation | 1 | 1.5 | -0.5 |
| Autism | 3.3 | 3.3 | 0 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1 | 0.5 | 1 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Carcinoma | 1.3 | 0.7 | 0.86 |
| Celiac Disease | 1.2 | 1 | 0.2 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 0.6 | 2.1 | -2.5 |
| Chronic Kidney Disease | 1.3 | 1.4 | -0.08 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.8 | -0.14 |
| Chronic Urticaria (Hives) | 0.3 | 0.5 | -0.67 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 1.6 | 0.8 | 1 |
| Colorectal Cancer | 3.8 | 1.1 | 2.45 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 0.3 | 0.8 | -1.67 |
| COVID-19 | 2.7 | 2.9 | -0.07 |
| Crohn's Disease | 2.8 | 1.3 | 1.15 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.5 | 1.1 | -1.2 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 3.3 | 2 | 0.65 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 1 | 0.5 | 1 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.6 | 1.2 | -1 |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 2 | 0.8 | 1.5 |
| Functional constipation / chronic idiopathic constipation | 1.7 | 2.4 | -0.41 |
| gallstone disease (gsd) | 0.4 | 0.5 | -0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.3 | 1 |
| Generalized anxiety disorder | 0.6 | 1.1 | -0.83 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.4 | 1.2 | 0.17 |
| Heart Failure | 1 | 0.5 | 1 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0 | 0.7 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2 | 1.4 | 0.43 |
| Hypoxia | 0.7 | 0.5 | 0.4 |
| IgA nephropathy (IgAN) | 1 | 1.1 | -0.1 |
| Inflammatory Bowel Disease | 2.3 | 2.2 | 0.05 |
| Insomnia | 0.6 | 1.1 | -0.83 |
| Intelligence | 0.3 | 0.5 | -0.67 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 1.7 | 2.2 | -0.29 |
| ischemic stroke | 1 | 0.8 | 0.25 |
| Liver Cirrhosis | 1.9 | 1.4 | 0.36 |
| Long COVID | 2.2 | 1.6 | 0.38 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.6 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2.1 | 2.5 | -0.19 |
| Mood Disorders | 2.6 | 2 | 0.3 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.1 | 2.4 | -0.14 |
| Multiple system atrophy (MSA) | 0.4 | 0.4 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 0.8 | 1.75 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.3 | 1.6 | 1.06 |
| obsessive-compulsive disorder | 1.6 | 1.7 | -0.06 |
| Osteoarthritis | 1.2 | 0.6 | 1 |
| Osteoporosis | 0.8 | 0.6 | 0.33 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2.5 | 2.3 | 0.09 |
| Polycystic ovary syndrome | 2.9 | 1.4 | 1.07 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 1.4 | 0.7 | 1 |
| Psoriasis | 0.3 | 2.1 | -6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 0.8 | 2 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 1.3 | 1.3 | 0 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 1.2 | 0.7 | 0.71 |
| Sleep Apnea | 0.8 | -0.8 | |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.3 | 0 |
| Systemic Lupus Erythematosus | 1.3 | 0.5 | 1.6 |
| Tic Disorder | 0.9 | 0.5 | 0.8 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.5 | 1.7 | -0.13 |
| Type 2 Diabetes | 2.7 | 2.2 | 0.23 |
| Ulcerative colitis | 2.2 | 2.7 | -0.23 |
| Unhealthy Ageing | 2.1 | 1 | 1.1 |
| Vitiligo | 1 | 0.4 | 1.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
